Key points are not available for this paper at this time.
Corrected T1 (cT1) is potential to be a novel imaging biomarker, which was based on T1 mapping corrected for iron content. The results of this study showed the high correlation between cT1 value and NAFLD activity, without correlation with fibrosis. There was high accuracy of cT1 to identify normal liver and liver with NAFLD, as well as mild and severe NAFLD. The severer inflammation, the higher heterogeneity of cT1 mapping. Thus, cT1 may be used for evaluating liver inflammation of patient with NAFLD, especially for those without severe fibrosis, and may evaluate heterogeneity further.
Li et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: